HR Execs on the Move

Akriveia Therapeutics

www.akrevia.com

 
`Akrevia` is derived from the Greek word for `precision`, which reflects our mission to precisely deliver the activity of potent, tailored immunotherapies exactly where it’s needed.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.akrevia.com
  • LabCentral 610 610 Main Street
    Cambridge, MA USA 02139
  • Phone: 602.226.2389

Executives

Name Title Contact Details

Similar Companies

Appleton Area Health Services

Appleton Area Health Services is a Appleton, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Celdara Medical

Celdara Medical gives hope and health to patients by transforming academic innovations into medicines that cure the world`s most challenging diseases. We are a recognized leader with a rich stable of discoveries, developed in concert with premiere research institutions in the US, EU, and beyond. We secure lasting partnerships with inventors and their institutions, and provide the developmental, financial, and business acumen to bridge the gaps between discovery and clinical impact. With robust funding options, operations in greater Boston, Washington DC and New York City, growing affiliates in Seattle and Indianapolis, a wealth of opportunities in our pipeline, and partnerships with industry leaders worldwide, Celdara Medical navigates the path from science to medicine, accelerating innovation to improve human health. Celdara Medical - Transforming innovation into medicine.™

Omeros Corporation

Omeros Corporation is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

iCo Therapeutics

iCo Therapeutics Inc. is a Vancouver-based development company focused on in-licensing drugs with clinical history redosing or reformulating for new or expanded indications. iCo has exclusive worldwide rights to three products. iCo-007, a second generation antisense candidate licensed from Isis Pharmaceuticals, is currently in a Phase I trial in Diabetic Macular Edema patients with compelling early data. iCo-008 is a human monoclonal antibody targeting eotaxin-1 with Phase II clinical history, licensed from AstraZeneca/MedImmune. iCo-009 is a proprietary oral formulation of amphotericin B licensed from the University of British Columbia.

Pharmagreen Biotech

harmagreen is a company focused on BIOTECH SCIENCES utilizing proprietary technologies and formulations in its state of the art CANNABIS BOTANY CENTER